F8 and hemophilia: Fitusiran is the first FDA-approved siRNA therapy (administered subcutaneously once monthly) by demonstrating positive effects from randomized controlled Phase III clinical trials across different types of hemophilia regardless of whether a patient has FVIII or FIX deficiency or the presence of plasma inhibitors (Lu et al., 2025).